Drug Discovery World

OCTOBER 31, 2023

The remaining 190 companies were then tested against assessment criteria based on ‘Impact potential’, ‘Differentiation’, ‘Breakthrough science/innovation’ and ‘Maturity’. There were also sections for Diagnostics and HealthTech.

Life Science 52

Life Science Drugs Research Development 52

pharmaphorum

AUGUST 16, 2022

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 It has also invested another $100 million in the three-year-old Cambridge, Massachusetts-based biotech, by participating in a $221 million Series B round.

RNA 98

RNA Vaccination Vaccine Clinical Trials 98

BioTech 365

MARCH 16, 2021

–(BUSINESS WIRE)–Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, … Continue reading →

Medicine 52

Medicine 52

pharmaphorum

JUNE 20, 2022

The paper says its source is the usual “people familiar with the matter” and stresses that a deal isn’t imminent, noting the regulatory challenges that may be faced given the strong position of both companies in the oncology category. It shows this is in fact a real issue holding some corners of biotech back.

Sales 105

Sales Marketing Drugs Licensing 105

pharmaphorum

JUNE 16, 2022

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to China’s HIBio. It also gets a $15 million signing fee related to MOR210.

Licensing 104

Licensing Licensing Antibody Sales 104

Drug Discovery Today

DECEMBER 4, 2019

SparingVision awarded First Prize in the Biotech category during the European EIT Health Summit held in Paris from 2 to 3 December

40

40

pharmaphorum

MAY 20, 2021

BMS wants to harness Exscientia’s tech to discover small-molecule drugs across a range of therapeutic categories – including immunology and oncology – and is promising another $125 million in near- and mid-term milestones to the project if all goes well. All told, the value of the deal could be as much as $1.2

Drugs 68

Drugs Pharma Companies Clinical Trials Clinical Trials 68

pharmaphorum

DECEMBER 2, 2021

The project is further evidence of a re-entry by GSK into neuroscience, a category that it has largely retreated from over the last decade in favour of investing more in cancer, vaccines and infectious disease, immunology and respiratory medicines. Milestone payments tied to progress of the two drugs could add another $1.5 billion to the pot.

Biobanking 92

Biobanking Genome Genomics Genetics 92

pharmaphorum

SEPTEMBER 28, 2022

Roche’s Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech’s programmable T cell-based therapies platform. Roche may be a relative latecomer to the cell therapy category, but it’s sparing no expense to build a position within it.

Gene Editing 58

Gene Editing Genome Genomics Engineer 58

Drug Discovery Today

JANUARY 13, 2020

Headstart start-ups address disease areas and challenges from Parkinson’s to obesity, with the innovations spanning the categories of medtech, digital health and biotech.

Marketing 40

Marketing 40

pharmaphorum

FEBRUARY 3, 2021

New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last year, with investment levels soaring to £2.8 The successful year means many UK biotechs are well capitalised as we head into 2021 with continuing high levels of global economic uncertainty,” says the report. billion ($3.8

Life Science 110

Life Science DNA Development Vaccination 110

pharmaphorum

AUGUST 5, 2022

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal.

Antibody 104

Antibody Immune Response Development Medicine 104

pharmaphorum

MAY 12, 2021

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . It’s also pledging milestones of up to $245 million per target, giving the entire deal an overall value of up to $1.25

RNA 71

RNA Protein Drugs Pharma Companies 71

pharmaphorum

JANUARY 27, 2023

The UK BioIndustry Association (BIA) and data and insights company Clarivate have released their annual UK Biotech Financing report – and, on the whole, the findings are not positive. While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines.

Life Science 52

Life Science Manufacturing Marketing Medicine 52

VirTrial

JANUARY 10, 2020

The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharma companies. VirTrial was recognized as the winner of the Digital Health Solutions category. Contact: Kim Kundert, VP, Clinical Operations. 480-229-1615.

Clinical Trials 97

Clinical Trials Clinical Trials Clinical Research Pharma Companies 97

pharmaphorum

SEPTEMBER 12, 2022

At the ESMO congress the German biotech reported updated results from a phase 1/2 trial of its lead candidate BNT-211 for solid tumours, which consists of a CAR-T directed at the antigen Claudin-6 on cancer cells, coupled with an mRNA vaccine (CARVac) designed to amplify the activity of the CAR-T.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

pharmaphorum

APRIL 13, 2022

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech’s shares skywards. GSK is paying $55 per share in cash for Sierra – a 39% premium to its closing share price yesterday – which values the company at around $1.9

Sales 105

Sales Production Antibody Trials 105

Intouch Solutions

FEBRUARY 2, 2022

Intouch Group and EVERSANA ENGAGE Named Gold and Silver Winners in Four Categories. Entries from Intouch Group earned gold in the professional campaign category, as well as two silver recognitions in the multichannel and variety categories. Congrats to everyone from both teams on this achievement.”.

Life Science 52

Life Science Marketing Production 52

pharmaphorum

NOVEMBER 22, 2022

The Series D comes a little over 18 months after the six-year-old biotech’s third-round financing netted it around $107 million, taking its total raised to date north of $360 million. Ut comes just as FogPharma is preparing to start clinical trials of alpha-helical polypeptide candidate FOG-001. According to FogPharma, in the U.

Gene Expression 52

Gene Expression Packaging Packaging Clinical Trials 52

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). The Swiss pharma group is paying $75 million upfronting cash and equity to get the ball rolling on the collaboration, with another $1.4

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

pharmaphorum

DECEMBER 8, 2021

China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive stage small cell lung cancer (ES-SCLC), setting up regulatory filings.

Drugs 98

Drugs Trials Clinical Trials Clinical Trials 98

pharmaphorum

JANUARY 13, 2022

The UK-headquartered pharma is buying into a drug discovery platform developed by Boston, US biotech Scorpion Therapeutics, paying $75 million upfront to get the ball rolling on the partnership, with undisclosed option fees and milestone payments also on offer.

Protein 58

Protein Gene Expression Regulation Gene 58

pharmaphorum

AUGUST 3, 2022

The Adaptimmune partnership followed a $2 billion alliance – including $300 million paid upfront – with Adaptive Biotech focusing on TCR therapies for solid tumours. Roche may be a latecomer to the cell therapy category – but it’s sparing no expense to build a position within it. Antibody for prurigo nodularis.

Licensing 98

Licensing Licensing Antibody Trials 98

pharmaphorum

JUNE 1, 2022

O-glycoproteins with truncated O-glycans are absent from normal tissues but are present in 60-80% of human epithelial cancers, according to the biotech. That’s a very broad category, spanning lung, breast, ovarian, gastric, colon, and pancreatic solid tumours.

Gene Therapy 98

Gene Therapy Clinical Development Antibody Gene 98

pharmaphorum

JULY 16, 2021

French drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden’s IRLAB for $28 million upfront. . The drug has since been discontinued.

Licensing 88

Licensing Licensing Cosmetics Drugs 88

pharmaphorum

MAY 5, 2022

One key example is the recently-introduced Access to Prescription Digital Therapeutics Act of 2022, which aims to officially define prescription digital therapeutics (PDTx) at the federal level and establish new Medicare and Medicaid benefit categories for the category. Similar initiatives are underway in German and France, he said.

Business Development 52

Business Development Medicine Production Marketing 52

pharmaphorum

AUGUST 1, 2022

Ipsen has joined the ranks of companies working on T cell receptor (TCR) therapies for cancer, paying $45 million upfront for rights to early-stage candidates developed by US biotech Marengo Therapeutics. The French pharma group has also promised around $1.6

Antibody 52

Antibody Clinical Trials Clinical Trials Development 52

pharmaphorum

SEPTEMBER 30, 2022

Novo Nordisk follows a number of other companies into the category, notably Roche which has acquired two NLRP3 inhibitor companies, licensing both peripherally-restricted and centrally-acting candidates. Novartis, meanwhile, bought US biotech IFM Tre – a subsidiary of IFM Therapeutics – in a deal worth up to $1.58

Drugs 58

Drugs Licensing Licensing Sales 58

Drug Discovery World

SEPTEMBER 6, 2022

The Informa Pharma Intelligence Awards Japan recognise outstanding innovations in Japanese pharma and biotech. The categories were judged by a panel of industry experts within academia and business from around Japan. . Licensing Deal of the Year recognises deals that were closed during 2021.

Licensing 52

Licensing Licensing Development Medicine 52

pharmaphorum

MAY 9, 2022

The new company – dubbed eureKING – plans to raise €150 million ($158 million) that will be used to buy up companies that operate in the European contract development and manufacturing organisation (CDMO) category. eureKARE initiated and is supporting the project.

Manufacturing 58

Manufacturing Gene Therapy Production Marketing 58

Advarra

MARCH 21, 2023

Interpreting evolving regulations for these devices is often a unique challenge for emerging biotech companies. Staying on top of evolving regulatory requirements for a complex medical device category can be overwhelming, even for well-established life science companies. How do you determine if clinical trials are needed for your device?

Clinical Trials 52

Clinical Trials Clinical Trials Trials Production 52

pharmaphorum

MAY 9, 2022

“At this time, the facts are still uncertain, and our decisions will be guided by the outcome of our investigation,” said Nancy Simonian, chair of the biotech’s nominating and corporate governance committee. billion last year.

Antibody 52

Antibody Sales Drugs Marketing 52

Drug Channels

JUNE 26, 2023

Cannot be combined with special category rates or other offers. This is a critical opportunity to navigate these complex yet beneficial partnerships with both health systems and life science companies together. Other restrictions may apply. The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc.,

Life Science 63

Life Science Pharmacy Drugs Manufacturing 63

pharmaphorum

SEPTEMBER 2, 2022

Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 The biotech went public via a $278 million IPO in 2020. Novo Nordisk licensed rights to EPI01 from EpiDestiny in 2018, paying $400 million for rights to the drug in haemaglobinopathies, while the biotech retained rights in oncology.

RNA 52

RNA Licensing Licensing Trials 52

pharmaphorum

APRIL 12, 2022

JDQ443 achieved a 57% overall response rate at a dose of 200mg given twice daily in the KontRASt-01 study, with a “favourable” side effect profile, and while Novartis is playing catch-up in the KRAS G12C inhibitor category the company thinks its drug could be best in class.

Drugs 98

Drugs Licensing Licensing Trials 98

pharmaphorum

NOVEMBER 22, 2022

Since then, the BCMA category has become more crowded, with two approved CAR-T therapies – Bristol-Myers Squibb/bluebird bio’s Abecma (idecabtagene vicleucel) and Johnson & Johnson/Legend Biotech’s CAR-T Carvykti (ciltacabtagene autoleucel) – as well as J&J’s BCMAxCD3 bispecific antibody Tecvayli (teclistamab).

Marketing 105

Marketing Trials Antibody Clinical Trials 105

XTalks

DECEMBER 15, 2020

With the acquisition, Syneos will add to its burgeoning portfolio that makes it the only fully integrated biopharmaceutical solutions organization in the biotech and pharma space. Funding for the biotech sector has been close to record highs and the upwards trajectory is expected to continue, according to industry estimates.

Dermatology 98

Dermatology Clinical Trials Clinical Trials Branding 98